Patents by Inventor Joseph Sodroski
Joseph Sodroski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11149069Abstract: The invention provides compositions and methods related to conformationally stabilizing primate immunodeficiency virus envelope glycoprotein trimers.Type: GrantFiled: July 31, 2013Date of Patent: October 19, 2021Assignee: Dana-Farber Cancer Institute, Inc.Inventors: Joseph Sodroski, Youdong Mao
-
Patent number: 10286057Abstract: The present invention relates, in general, to human immunodeficiency virus (HIV), and, in particular, to a vaccine for HIV-1, comprising synthetic V3 glycopeptides, and to methods of making and using same.Type: GrantFiled: April 15, 2014Date of Patent: May 14, 2019Assignees: Duke University, Sloan-Kettering Institute for Cancer Research, Dana-Farber Cancer Institute, Inc.Inventors: Barton F. Haynes, Hua-xin Liao, Samuel Danishefsky, Peter Park, Joseph Sodroski, Baptiste Aussedat, Yusuf Vohra
-
Patent number: 9975848Abstract: The disclosure provides compositions and methods for sensitizing primary HIV-1, including transmitted/founder viruses, to neutralization by monoclonal antibodies, e.g., those directed against CD4-induced (CD4i) epitopes and the V3 region. In certain embodiments, the disclosure relates to the use of small molecules as microbicides to inhibit HIV-1 infection directly and to sensitize primary HIV-1 to neutralization by readily elicited antibodies.Type: GrantFiled: August 13, 2015Date of Patent: May 22, 2018Assignees: The Trustees of the University of Pennsylvania, Dana-Farber Cancer Institute, Inc., Bryn Mawr CollegeInventors: Amos B. Smith, III, Joseph Sodroski, Navid Madani, Bruno Melillo, Judith M. LaLonde, Amy M. Princiotto
-
Patent number: 9855329Abstract: Disclosed herein are mosaic HIV envelope (Env) polypeptides that can elicit an immune response to HIV (such as cytotoxic T cell (CTL), helper T cell, and/or humoral responses). Also disclosed are sets of the disclosed mosaic Env polypeptides, which include two or more (for example, three) of the polypeptides. Also disclosed herein are methods for treating or inhibiting HIV in a subject including administering one or more of the disclosed immunogenic polypeptides or compositions to a subject infected with HIV or at risk of HIV infection. In some embodiments, the methods include inducing an immune response to HIV in a subject comprising administering to the subject at least one (such as two, three, or more) of the immunogenic polypeptides or at least one (such as two, three, or more) nucleic acids encoding at least one of the immunogenic polypeptides disclosed herein.Type: GrantFiled: September 30, 2014Date of Patent: January 2, 2018Assignees: Los Alamos National Security, LLC, Dana-Farber Cancer Institute, Duke UniversityInventors: Bette T. M. Korber, S. Gnanakaran, Simon Perkins, Joseph Sodroski, Barton Haynes
-
Publication number: 20170298056Abstract: Described herein are small-molecule compounds that specifically inhibit a wide range of HIV-1 isolates without interfering with CD4 or CCR5 binding. Methods of using die compounds for treating or preventing HIV infection are also described.Type: ApplicationFiled: May 8, 2015Publication date: October 19, 2017Inventors: Joseph Sodroski, Alon Herschhorn, Christopher Gu, Joel R. Courter, Mark Farrell, Amos B. Smith, III
-
Publication number: 20170233335Abstract: The disclosure provides compositions and methods for sensitizing primary HIV-1, including transmitted/founder viruses, to neutralization by monoclonal antibodies, e.g., those directed against CD4-induced (CD4i) epitopes and the V3 region. In certain embodiments, the disclosure relates to the use of small molecules as microbicides to inhibit HIV-1 infection directly and to sensitize primary HIV-1 to neutralization by readily elicited antibodies.Type: ApplicationFiled: August 13, 2015Publication date: August 17, 2017Inventors: Amos B. SMITH,, III, Joseph SODROSKI, Navid MADANI, Bruno MELILLO, Judith M. LALONDE, Amy M. PRINCIOTTO
-
Publication number: 20160362478Abstract: Described herein are methods of generating a protein binding domain that specifically binds to gp120 in a specific conformational state, comprising contacting gp120 with a CD4-mimetic compound, thereby forming gp120 in the specific conformational state; and generating antibodies to gp120 in the specific conformation state. Relatedly, the disclosure also describes methods of neutralizing HIV-1, comprising contacting HIV-1 with an effective amount of a CD4-mimetic compound, thereby forming HIV-1 having gp120 in a specific conformational state; and contacting the HIV-1 in the specific conformational state with an antibody.Type: ApplicationFiled: February 10, 2015Publication date: December 15, 2016Inventors: Joseph SODROSKI, Navid MADANI, Amy M. PRINCIOTTO, Arne SCHON, Judith M. LaLONDE, Ernesto FREIRE, Amos B. SMITH, Richard T. WYATT, Jongwoo PARK, Joel R. COURTER, David M. JONES, Wayne A. HENDRICKSON, Xueling WU, Matthew LE-KHAC, Peter D. KWONG, Young Do KWON, John R. MASCOLA
-
Publication number: 20160235836Abstract: Disclosed herein are mosaic HIV envelope (Env) polypeptides that can elicit an immune response to HIV (such as cytotoxic T cell (CTL), helper T cell, and/or humoral responses). Also disclosed are sets of the disclosed mosaic Env polypeptides, which include two or more (for example, three) of the polypeptides. Also disclosed herein are methods for treating or inhibiting HIV in a subject including administering one or more of the disclosed immunogenic polypeptides or compositions to a subject infected with HIV or at risk of HIV infection. In some embodiments, the methods include inducing an immune response to HIV in a subject comprising administering to the subject at least one (such as two, three, or more) of the immunogenic polypeptides or at least one (such as two, three, or more) nucleic acids encoding at least one of the immunogenic polypeptides disclosed herein.Type: ApplicationFiled: September 30, 2014Publication date: August 18, 2016Applicants: Los Alamos National Security, LC/TAS, Duke University, Dana-Farber Cancer InstituteInventors: Bette T.M. Korber, S. Gnanakaran, Simon Perkins, Joseph Sodroski, Barton Haynes
-
Patent number: 9403763Abstract: Described herein are small-molecule mimics of CD4, which both enter the Phe43 cavity and target Asp368 of gp120, the HIV-1 envelope protein. Also described herein are methods of using these compounds to inhibit the transmission or progression of HIV infection. These compounds exhibit antiviral potency greater than that of a known antiviral, NBD-556, with 100% breadth against clade B and C viruses. Importantly, the compounds do not activate HIV infection of CD4-negative, CCR5-positive cells, in contrast to NBD-556.Type: GrantFiled: December 14, 2012Date of Patent: August 2, 2016Inventors: Joseph Sodroski, Judith M. LaLonde, Amos B. Smith, III, Peter D. Kwong, Young Do Kwon, David M. Jones, Alexander W. Sun, Joel R. Courter, Takahiro Soeta, Toyoharu Kobayashi, Amy M. Princiotto, Xueling Wu, John R. Mascola, Arne Schon, Ernesto Freire, Navid Madani, Matthew Le-Khac, Wayne A. Hendrickson, Jongwoo Park
-
Publication number: 20160106827Abstract: The present invention relates, in general, to human immunodeficiency virus (HIV), and, in particular, to a vaccine for HIV-1, comprising synthetic V3 glycopeptides, and to methods of making and using same.Type: ApplicationFiled: April 15, 2014Publication date: April 21, 2016Inventors: Barton F. Haynes, Hua-xin Liao, Samuel Danishefsky, Peter Park, Joseph Sodroski, Baptiste Aussedat, Yusuf Vohra
-
Publication number: 20150283227Abstract: The present invention relates, in general, to human immunodeficiency virus-1 (HIV-1), and, in particular to a vaccine for HIV-1 and to methods of making and using same. The present invention provides synthetic glycosylated HIV-1 peptides, method for their preparation and use.Type: ApplicationFiled: October 28, 2013Publication date: October 8, 2015Inventors: Barton F. Haynes, Hua-Xin Liao, S. Munir Alam, Samuel Danishefsky, Baptiste Aussedat, Peter K. Park, Yusuf Vohra, Joseph Sodroski
-
Publication number: 20150183836Abstract: The invention provides compositions and methods related to conformationally stabilizing primate immunodeficiency virus envelope glycoprotein trimers.Type: ApplicationFiled: July 31, 2013Publication date: July 2, 2015Applicant: Dana-Farber Cancer Institute, Inc.Inventors: Joseph Sodroski, Youdong Mao
-
Publication number: 20140350113Abstract: Described herein are small-molecule mimics of CD4, which both enter the Phe43 cavity and target Asp368 of gp120, the HIV-1 envelope protein. Also described herein are methods of using these compounds to inhibit the transmission or progression of HIV infection. These compounds exhibit antiviral potency greater than that of a known antiviral, NBD-556, with 100% breadth against clade B and C viruses. Importantly, the compounds do not activate HIV infection of CD4-negative, CCR5-positive cells, in contrast to NBD-556.Type: ApplicationFiled: December 14, 2012Publication date: November 27, 2014Inventors: Joseph Sodroski, Judith M. LaLonde, Amos B. Smith, III, Peter D. Kwong, Young Do Kwon, David M. Jones, Alexander W. Sun, Joel R. Courter, Takahiro Soeta, Toyoharu Kobayashi, Amy M. Princiotto, Xueling Wu, John R. Mascola, Ame Schon, Emesto Freire, Navid Madani, Matthew Le-Khac, Wayne A. Hendrickson
-
Patent number: 8715686Abstract: Isolated immunogens including a HIV-1 gp120 polypeptide or immunogenic fragment thereof stabilized in a CD4 bound confirmation by crosslinked cysteines, and methods of their use are disclosed. The immunogens are useful, for example, for generating an immune response to HIV-1 gp120 in a subject.Type: GrantFiled: August 14, 2012Date of Patent: May 6, 2014Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Dana-Faber Cancer Institute, Inc.Inventors: Peter Kwong, John Mascola, Gary Nabel, Richard Wyatt, Barna Dey, Ling Xu, Tongqing Zhou, Joseph Sodroski, Wen Yuan, Shi-Hua Xiang
-
Publication number: 20120328641Abstract: Stabilized forms of gp120 polypeptide, nucleic acids encoding these stabilized forms, vectors comprising these nucleic acids, and methods of using these polypeptides, nucleic acids, vectors and host cells are disclosed. Crystal structures and computer systems including atomic coordinates for stabilized forms of gp120, and gp120 with an extended V3 loop, and methods of using these structures and computer systems are also disclosed.Type: ApplicationFiled: August 14, 2012Publication date: December 27, 2012Inventors: Peter Kwong, John Mascola, Gary Nabel, Richard Wyatt, Barna Dey, Ling Xu, Tongqing Zhou, Joseph Sodroski, Wen Yuan, Shi-Hua Xiang
-
Patent number: 8309697Abstract: The invention provides novel TRIM polypeptides, proteins, and nucleic acid molecules. In addition to isolated, full-length TRIM proteins, the invention further provides isolated TRIM fusion proteins, antigenic peptides and anti-TRIM antibodies. The invention also provides TRIM nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which an TRIM gene has been introduced or disrupted. The present invention also provides methods and compositions for the diagnosis and treatment of viral infection and/or replication, e.g., HIV infection. The invention further provides methods for identifying a compound capable of treating or preventing viral infection and/or replication, e.g., HIV infection and AIDS. In addition, the invention provides a method for treating a subject having a viral infection and/or replication, e.g.Type: GrantFiled: January 19, 2010Date of Patent: November 13, 2012Assignee: Dana-Farber Cancer Institute, Inc.Inventors: Joseph Sodroski, Matthew Stremlau, Christopher M. Owens
-
Patent number: 8268323Abstract: Stabilized forms of gp120 polypeptide, nucleic acids encoding these stabilized forms, vectors comprising these nucleic acids, and methods of using these polypeptides, nucleic acids, vectors and host cells are disclosed. Crystal structures and computer systems including atomic coordinates for stabilized forms of gp120, and gp120 with an extended V3 loop, and methods of using these structures and computer systems are also disclosed.Type: GrantFiled: September 14, 2011Date of Patent: September 18, 2012Assignees: The United States of America as represented by the Secretary of the Department of Health and Human Services, Dana Farber Cancer Institute, Inc.Inventors: Peter Kwong, John Mascola, Gary Nabel, Richard Wyatt, Barna Dey, Ling Xu, Tongqing Zhou, Joseph Sodroski, Wen Yuan, Shi-Hua Xiang
-
Publication number: 20120122834Abstract: The invention provides for compounds of formula I: wherein Z is absent or (CRARB)nW; each RA and RB is independently (i) H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, haloalkyl, each of which may be optionally substituted; (ii) OH, ORc, NH2, NHL, NRcRc, SH, S(O)mRc; or (iii) RA and RB together form C(O); W is absent, C(O), C(O)O, C(O)NRcRc, O, S(O)m, or NRcRc; Y is an optionally substituted heterocyclic, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted aryl, or NRXRY; wherein Rx and Ry are each independently H, alkyl or aryl; X1 is selected from the group consisting of halogen, methyl, and hydroxyl; X2 is a halogen; each Rc is independently alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, or heteroaralkyl, each of which may be optionally substituted; m is O, 1, or 2; and n is 1, 2, 3, 4, 5, or 6; and pharmaceutically acceptable salts thereof.Type: ApplicationFiled: November 10, 2009Publication date: May 17, 2012Applicants: DANA-FARBER CANCER INSTITUTE, INC., UNIVERSITY OF PENNSYLVANIA, JOHNS HOPKINS UNIVERSITYInventors: Joseph Sodroski, Navid Madani, Arne Schon, Judith M. La Londe, Joel R. Courter, Takahiro Soeta, Danny Ng, Ernesto Freire, Amos B. Smith, III
-
Publication number: 20120034255Abstract: Stabilized forms of gp120 polypeptide, nucleic acids encoding these stabilized forms, vectors comprising these nucleic acids, and methods of using these polypeptides, nucleic acids, vectors and host cells are disclosed. Crystal structures and computer systems including atomic coordinates for stabilized forms of gp120, and gp120 with an extended V3 loop, and methods of using these structures and computer systems are also disclosed.Type: ApplicationFiled: September 14, 2011Publication date: February 9, 2012Inventors: Peter Kwong, John Mascola, Gary Nabel, Richard Wyatt, Barna Dey, Ling Xu, Tongqing Zhou, Joseph Sodroski, Wen Yuan, Shi-Hua Xiang
-
Patent number: 8044185Abstract: Stabilized forms of gp120 polypeptide, nucleic acids encoding these stabilized forms, vectors comprising these nucleic acids, and methods of using these polypeptides, nucleic acids, vectors and host cells are disclosed. Crystal structures and computer systems including atomic coordinates for stabilized forms of gp120, and gp120 with an extended V3 loop, and methods of using these structures and computer systems are also disclosed.Type: GrantFiled: September 6, 2006Date of Patent: October 25, 2011Assignees: The United States of America as represented by the Secretary of the Department of Health and Human Services, Dana Farber Cancer Institute, Inc.Inventors: Peter Kwong, John Mascola, Gary Nabel, Richard Wyatt, Barna Dey, Ling Xu, Tongqing Zhou, Chih-Chin Huang, Joseph Sodroski, Wen Yuan, Shi-Hua Xiang